Jennifer Lachey, Chief Scientific Officer at Keros Therapeutics, Inc. (KROS), sold 4,183 shares at $50.37 ($212K) on 2021-06-11, disclosed to the SEC on 2021-06-15.
Open-market sale of $212k KROS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.37 | 1,533 | $77K | 36.4% |
| 2 | $50.37 | 1,533 | $77K | 36.4% |
| 3 | $51.73 | 898 | $46K | 21.9% |
| 4 | $52.13 | 219 | $11K | 5.4% |
| Total | $50.75 avg | 4,183 | $212K | 100% |
| Filing → |
| KROS | SELL | 2022-05-13 | $362K | — | Filing → |
| KROS | SELL | 2022-04-13 | $630K | — | Filing → |
| KROS | SELL | 2022-04-06 | $477K | — | Filing → |